OncoMatch/Clinical Trials/NCT07336823
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Is NCT07336823 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies JY232 for multiple myeloma.
Treatment: JY232 — This study is an investigator-initiated single center, single arm clinical study with a target population of patients with relapsed/refractory multiple myeloma. It is an early exploratory clinical study of the safety, tolerability and initial efficacy of JY232 injection in the treatment of relapsed/refractory multiple myeloma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Biomarker criteria
Required: BCMA (TNFRSF17) expression on plasma cell membrane (positive by IHC or flow cytometry)
tumor sample (bone marrow) tests positive for B-Cell Maturation Antigen (BCMA) expression on the plasma cell membrane via immunohistochemistry (IHC) or flow cytometry
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: immunomodulatory drug
Must have received at least 2 prior lines of anti-MM therapy (including immunomodulatory drugs, proteasome inhibitors, and anti-Cluster of Differentiation 38 (CD38) therapy, as single agents or in combination. Patients who are intolerant or have contraindications to these therapies are eligible for enrollment if they meet other inclusion/exclusion criteria).
Must have received: proteasome inhibitor
Must have received at least 2 prior lines of anti-MM therapy (including immunomodulatory drugs, proteasome inhibitors, and anti-Cluster of Differentiation 38 (CD38) therapy, as single agents or in combination. Patients who are intolerant or have contraindications to these therapies are eligible for enrollment if they meet other inclusion/exclusion criteria).
Must have received: anti-CD38 therapy
Must have received at least 2 prior lines of anti-MM therapy (including immunomodulatory drugs, proteasome inhibitors, and anti-Cluster of Differentiation 38 (CD38) therapy, as single agents or in combination. Patients who are intolerant or have contraindications to these therapies are eligible for enrollment if they meet other inclusion/exclusion criteria).
Cannot have received: monoclonal antibody therapy
Exception: within 21 days prior to dosing or within at least 5 half-lives (whichever is longer)
Monoclonal antibody therapy for multiple myeloma (MM) within 21 days prior to dosing or within at least 5 half-lives (whichever is longer)
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Cytotoxic chemotherapy within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Cannot have received: proteasome inhibitor
Exception: within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Proteasome inhibitor or immunomodulatory agent therapy within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Cannot have received: immunomodulatory drug
Exception: within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Proteasome inhibitor or immunomodulatory agent therapy within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Cannot have received: investigational drug
Exception: within 30 days prior to screening or within 5 half-lives (whichever is longer), or still within the washout period
Treatment with investigational drugs within 30 days prior to screening or within 5 half-lives (whichever is longer), or still within the washout period; or treatment involving invasive investigational medical devices
Cannot have received: radiation therapy
Exception: within 4 weeks prior to dosing
Radiotherapy within 4 weeks prior to dosing
Cannot have received: other anti-tumor therapies
Exception: within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Other anti-tumor therapies not listed above within 14 days prior to dosing or within at least 5 half-lives (whichever is longer)
Lab requirements
Blood counts
ANC ≥ 1×10^9 /L (growth factor support allowed, but not within 7 days prior to test); ALC ≥0.3×10^9 /L; Platelets ≥50×10^9 /L (no transfusion within 7 days); Hemoglobin ≥60 g/L (no RBC transfusion within 7 days; recombinant human erythropoietin allowed)
Kidney function
CrCl from 24-hour urine collection or Cockcroft-Gault formula ≥ 40 ml/min
Liver function
ALT and AST ≤2.5 × ULN; Serum total bilirubin ≤1.5 × ULN
Cardiac function
LVEF ≥ 50%; No clinically significant pericardial effusion detected
The subject must have adequate organ function, meeting all the following laboratory results prior to enrollment: ... (see full criteria for details)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify